ConductScience.org, home

Paper39600709

Biomaterials' enhancement of immunotherapy for breast cancer by targeting functional cells in the tumor micro-environment.

Santerre JP and 4 others. Front Immunol, 2024. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. Biomaterials' enhancement of immunotherapy for breast cancer by targeting functional cells in the tumor micro-environment. Papers, record 39600709. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39600709

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Biomaterials' enhancement of immunotherapy for breast cancer by targeting functional cells in the tumor micro-environment.
PubMed
Journal
Front Immunol
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
0.95, provisional
iCite
Revised in PubMed
2026-10-08
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Santerre JPJ Paul
2Yang YYangyang
3Du ZZiwei
4Wang WWenshuang
5Zhang XXiaoqing

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Tumor MicroenvironmentMajor topic
Breast NeoplasmsMajor topic
ImmunotherapyMajor topic
Biocompatible MaterialsMajor topic
Humans
Female
Animals
Nanoparticles

Source PubMed

Download CSV of topics

References182

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138141488
Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT).
Lung Cancer2024https://conductscience.org/library/papers/38141488PubMed
225345674The immune checkpoint inhibitors: where are we now?Nat Rev Drug Discov2014https://conductscience.org/library/papers/25345674PubMed
334551052DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy.J Mater Chem B2021https://conductscience.org/library/papers/34551052PubMed
433256070Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer.Cancers (Basel)2020https://conductscience.org/library/papers/33256070PubMed
528487109CCR4 mediated chemotaxis of regulatory T cells suppress the activation of T cells and NK cells via TGF-β pathway in human non-small cell lung cancer.Biochem Biophys Res Commun2017https://conductscience.org/library/papers/28487109PubMed
622788954Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.Breast Cancer Res2012https://conductscience.org/library/papers/22788954PubMed
724762078Dendritic cell-based vaccines: clinical applications in breast cancer.Immunotherapy2014https://conductscience.org/library/papers/24762078PubMed
840395757Antigen/adjuvant-free liposome induces adjuvant effects for enhancing cancer immunotherapy.Exploration (Beijing)2025https://conductscience.org/library/papers/40395757PubMed
936797782NK cells are never alone: crosstalk and communication in tumour microenvironments.Mol Cancer2023https://conductscience.org/library/papers/36797782PubMed
1037496657The role of cancer-associated fibroblasts in breast cancer metastasis.Front Oncol2023https://conductscience.org/library/papers/37496657PubMed
1130734283In search of definitions: Cancer-associated fibroblasts and their markers.Int J Cancer2020https://conductscience.org/library/papers/30734283PubMed
1231670078Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy.Biomaterials2020https://conductscience.org/library/papers/31670078PubMed
1331022431Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization.J Control Release2019https://conductscience.org/library/papers/31022431PubMed
1436925703Biomimetic cell membrane-coated poly(lactic-co-glycolic acid) nanoparticles for biomedical applications.Bioeng Transl Med2023https://conductscience.org/library/papers/36925703PubMed
1535647515A ROS-responsive synergistic delivery system for combined immunotherapy and chemotherapy.Mater Today Bio2022https://conductscience.org/library/papers/35647515PubMed
1627782834Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens.J Exp Clin Cancer Res2016https://conductscience.org/library/papers/27782834PubMed
1734209703Macrophage Polarization States in the Tumor Microenvironment.Int J Mol Sci2021https://conductscience.org/library/papers/34209703PubMed
1832849585The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.Front Immunol2020https://conductscience.org/library/papers/32849585PubMed
1933587080Tumor-targeted gene therapy with lipid nanoparticles inhibits tumor-associated adipocytes and remodels the immunosuppressive tumor microenvironment in triple-negative breast cancer.Nanoscale Horiz2021https://conductscience.org/library/papers/33587080PubMed
2030465162Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment.Cancer Metastasis Rev2018https://conductscience.org/library/papers/30465162PubMed

See all 182 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42445830Breaking the Barrier of Tumor Hypoxia: Oxygen-Enhancing Nano Biomaterials in Cancer Therapy.Int J Nanomedicine2026https://conductscience.org/library/papers/42445830PubMed
41933234Emerging nanoimmunotherapeutic strategies for breast cancer.Discov Oncol2026https://conductscience.org/library/papers/41933234PubMed
41828419Autophagy Modulation in Cancer Immunotherapy, Emerging Molecular Targets and Drug Selection Strategies.Int J Mol Sci2026https://conductscience.org/library/papers/41828419PubMed
41258978Drug Repurposing in Oncology: A Strategic Pathway to Unlocking New Therapeutic Potential.Ther Innov Regul Sci2026https://conductscience.org/library/papers/41258978PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39600709

GET https://conductscience.org/api/papers/v1/39600709/references?page=2